1. The use of diazoxide or its pharmaceutically acceptable salt as a medicine in a daily dose of 0.15 mg / m / day to 13.00 mg / m / day based on the free base of the diazoxide in the treatment of a mammal from amyotrophic lateral sclerosis. 2. The use according to claim 1, in which the diazoxide is a free base. The use of claim 1, wherein the mammal is a human. The use according to claim 1, in which the drug is made for oral administration. The use according to claim 1, in which the drug is made for the introduction of diazoxide in a daily dose of from 0.15 mg / m / day to 3.00 mg / m / day. The use according to claim 5, in which the drug is prepared for the introduction of diazoxide in a daily dose of 2.40 mg / m / day to 3.00 mg / m / day. The use according to any one of claims 1 to 4, in which the drug is prepared for the administration of diazoxide in a daily dose selected from the group of doses comprising 0.15 mg / m / day, 2.22 mg / m / day, 2.40 mg / m / day, 2.96 mg / m / day, 3.00 mg / m / day and 11.1 mg / m / day. 8. The use according to claim 1, in which the diazoxide is the only therapeutic substance in the drug. The use of claim 1, wherein the medicament consists of a diazoxide and of at least one therapeutic substance pharmaceutically acceptable for the treatment of amyotrophic lateral sclerosis. The use according to claim 9, in which the additional therapeutic substance is selected from the group of substances including SC-2017357, olesoxime (TRO 19622), arimoclomol, riluzole, tretionine and pioglitazone hydrochloride, AVP-923, memantine, thalampanel, taurourodesodeoxycholic acid, thalidomide, olanidase, olanidazide , KNS-760704, lithium carbonate, NP001, ONO-2506PO, tamoxifen, cr monohydrate1. Применение диазоксида или его фармацевтически приемлемой соли в качестве лекарственного средства в суточной дозе от 0,15 мг/м/день до 13,00 мг/м/день в расчете на свободное основание диазоксида при лечении млекопитающего от бокового амиотрофического склероза
